Pens are designed around a “standard” dose schedule, but real humans rarely fit the factory template. Doctors may intentionally prescribe doses that don’t divide neatly into four, because:

• Some patients need slower dose increases to manage side effects.
• Others stabilise at doses between the standard steps.
• Certain medical conditions require more precise titration.
• The prescribed dose may be lower than the labelled pen strength, so the pen naturally lasts longer.

Exploring how different click settings translate into dose and volume can help patients understand what their doctor has prescribed and why the number of doses per pen may not always be exactly four.

Education, not self-dosing.

Sometimes, yes – but only when your doctor has intentionally set it up that way. In some health systems, the cost of a higher-strength pen is similar to the lower-strength version. A doctor may prescribe a stronger pen (for example, a 15 mg pen) but instruct you to use smaller doses so the pen lasts longer. The per-milligram cost can end up lower for the patient.

That can be a legitimate, ethical strategy when:

• The dose plan is written and explained by your prescriber.
• They’ve confirmed the click settings that match your actual dose.
• They’ve checked for safety issues, insurance rules and local regulations.

Dose changes without medical supervision can increase side effects, reduce effectiveness and may breach treatment or subsidy rules.

Personally, I think it’s OK provided you do so carefully and fully informed. But technically, the answer of course is NO. Changing your dose without medical advice is risky. Even “small” adjustments can:

• Increase nausea, vomiting or dehydration.
• Cause too much appetite suppression or rapid weight loss.
• Interact badly with other conditions or medications.
• Undermine the long-term benefit of treatment.

If you think your dose is too high, too low or unaffordable, the correct next step is to speak with your prescriber, not to experiment with the pen.

Manufacturers usually overfill pens slightly so that every patient can reliably receive the full labelled dose even if tiny amounts remain in the device. That means:

• You may notice extra clicks or a little fluid left after the labelled doses.
• This is a manufacturing buffer, not a bonus dose.

Your doctor may or may not consider this overfill relevant when planning your dose schedule. The calculator simply shows the maths; it doesn’t tell you to use the leftovers.

The calculator may show that, mathematically, a particular click setting could yield more than four doses. That doesn’t automatically mean those extra doses are appropriate or safe for you.

In many cases, using the pen beyond the prescribed schedule:

• pushes the weekly dose above what your doctor intended, or
• falls outside the way the product was tested and approved.

If your doctor wants you to use more doses per pen for clinical or cost reasons, they will tell you exactly how many clicks to use and how long to keep the pen.

A “Golden Dose” is an unofficial term people use for an extra dose that can sometimes be removed from a pen because manufacturers intentionally overfill them. That overfill exists so every patient receives the full labelled doses even after priming and tiny losses inside the device.

Some people online claim you can extract this leftover volume using a manual syringe or by manipulating the device to access the final bit of fluid. This extra amount is what they call the “Golden Dose”.

But it’s important to understand: this leftover volume is not a bonus dose, it’s not calibrated, and it’s not guaranteed. It varies between pens, lots, manufacturers and fill tolerances. It also hasn’t been tested or approved for use outside the normal dosing instructions.

Your doctor may or may not factor this manufacturing overfill into your treatment plan. The calculator simply shows the maths; it does not recommend extracting leftover medication or using non-standard administration methods.

Yes. The multi-dose Mounjaro KwikPens used in this calculator all hold the same total volume of liquid – around 2.4 mL per pen. That volume is designed to provide four standard 0.6 mL doses, regardless of whether the pen is 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg or 15 mg.

What changes between pens is not the amount of liquid, but the concentration of the medicine in that liquid. Higher-strength pens contain more medication per mL, so each click delivers more milligrams, even though the mL per click is the same.

For example, each click is roughly 0.01 mL across all pens. On a 2.5 mg pen that’s about 0.04 mg per click, while on a 15 mg pen it’s about 0.25 mg per click. Same volume, different strength.

That’s why the chart (and this calculator) can use the same click and volume values for every pen, but the mg dose changes depending on which pen strength you choose.

This explanation is for information only. Any changes to your dose, pen strength, or how you use your pen should always be discussed with your prescribing clinician or pharmacist.

The calculator is a visual explanation tool. It helps you see how:

• clicks relate to dose (mg) and volume (mL)
• different settings change the number of doses per pen
• a doctor-prescribed non-standard dose compares to the “standard” dose

That understanding can make it easier to follow your prescriber’s instructions correctly, ask better questions in appointments and spot obvious misunderstandings before you inject.

Your doctor is. Always.

The calculator uses a simplified model based on typical pen settings and volumes. Your prescriber may be using a different pen, a different formulation, updated clinical guidance or an individualised plan that doesn’t line up perfectly with the tool.

If something doesn’t match, treat that as a prompt to ask your clinician to double-check the dose and click settings with you. Do not “correct” your dose to match the calculator.

Always start with the health professional who prescribed the medication. They can:

• adjust your dose or titration speed if side effects are a problem,
• discuss whether a different pen strength or schedule could be more affordable,
• check that you’re using the device correctly, and
• review interactions with other conditions or medicines.

Pharmacists can also help explain device mechanics and cost differences between pen strengths, but they should not overrule your prescriber on dose.

Mounjaro is a prescription-only medication, and how you access it depends on your country:

• Australia: Mounjaro can only be prescribed by a registered medical practitioner such as a GP or specialist. Once prescribed, it is dispensed through community pharmacies.
• United States, UK, Canada, EU and other regions: Regulations vary, but Mounjaro is generally available only with a prescription from a licensed healthcare professional and filled through authorised pharmacies.

Mounjaro should never be purchased from unverified online sellers or social media vendors, as counterfeit and unsafe products are common. Always follow local medical and pharmacy regulations.

Yes. Several medications work on similar hormone pathways and may be prescribed for type 2 diabetes or weight-related conditions. The most common alternatives include:

• Ozempic (semaglutide):
  A weekly GLP-1 receptor agonist used for type 2 diabetes. Often prescribed off-label for weight loss where Wegovy is not available.
• Wegovy (semaglutide):
  A higher-dose version of semaglutide approved specifically for weight management in many countries. Similar mechanism to Ozempic but typically produces greater weight loss at approved doses.
• Saxenda (liraglutide):
  A daily GLP-1 injection for weight management. Effective, but generally produces less weight loss than weekly medications and may have more day-to-day side effects.
• Trulicity (dulaglutide):
  Another weekly GLP-1 medication for type 2 diabetes. Not usually used for weight management, but some people experience modest weight loss.
• Oral options (e.g., Rybelsus):
  A tablet form of semaglutide taken daily. Useful for people who prefer not to inject, though weight-loss effects may be milder than injectables.

Each medication differs in effectiveness, side-effect profile, dosing schedule, and availability. Some are easier to tolerate during dose escalation, while others may work better for weight loss. Your prescriber can advise which option is safest and most appropriate depending on your medical history and what is approved in your country.

Yes. Several next-generation medications are in late-stage development or beginning to roll out in certain countries. These drugs are designed to improve on current GLP-1 and dual-agonist treatments by targeting additional metabolic pathways or offering stronger effects at lower doses.

• Retatrutide:
  A promising tri-agonist (GLP-1, GIP, and glucagon receptors) currently in clinical trials. Early results show significantly greater weight-loss potential than existing medications including semaglutide and tirzepatide.
• Cagrilintide + Semaglutide:
  A combination of amylin analogue (cagrilintide) with semaglutide. Trials have shown enhanced appetite-control effects compared with semaglutide alone.
• Orforglipron:
  A once-daily oral GLP-1 agonist in development. Early data suggests weight-loss results similar to injectable GLP-1 medications, which could be a major shift for people who prefer tablets.
• Efinopegdutide:
  Another investigational medication showing strong early results for weight reduction and metabolic control.
• Longer-acting or monthly GLP-1 / GIP medicines:
  Several pharmaceutical companies are working on versions that require fewer injections, which may reduce side-effects from rapid dose escalation.

These medications are still undergoing clinical trials and regulatory review. Availability will vary by country, and approval may take several years. Your doctor or pharmacist will have the most up-to-date information once these options become approved and accessible.